Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.270
+0.310 (7.83%)
At close: Apr 28, 2026, 4:00 PM EDT
4.140
-0.130 (-3.04%)
After-hours: Apr 28, 2026, 7:45 PM EDT
Company Description
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Andrew Goldberg |
Contact Details
Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Mark K. Oki CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | SCHEDULE 13D | Filing |
| Apr 24, 2026 | SCHEDULE 13G | Filing |
| Apr 24, 2026 | SCHEDULE 13D | Filing |
| Apr 24, 2026 | SCHEDULE 13G | Filing |
| Apr 24, 2026 | SCHEDULE 13G | Filing |
| Apr 16, 2026 | 8-K | Current Report |
| Apr 16, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |